- Technology and Data
- Front End Sales and Marketing
- Allergy
- HIV
- Women's Health
- Migraine
- Compounding
- Continuous Glucose Monitoring
- Mental Health Awareness
- Veterinary Pharmacy
- CBD
- Infectious Disease
- Eye Health
- Digestive Health
- Biosimilars
- Influenza
- Shingles
- COPD Management
- Pediatrics
- Generics
- Pain Management
- COVID-19
- Immunization
- Oncology
- Anticoagulants
- Autoimmune Diseases
- Dermatology
- Diabetes
- Respiratory
- Heart Health
- Cardiovascular Clinical Consult
Walgreens shares down after soft earnings report
Despite increases in earnings and net income, Walgreens shares dropped this week after the company’s third-quarter earnings fell short of Wall Street expectations.
Despite increases in earnings and net income, Walgreens shares dropped this week after the company’s third-quarter earnings fell short of Wall Street expectations.
The company’s adjusted earnings for the quarter increased 29.3% to $812 million, or 85 cents a share. That was 6 cents less than what analysts forecast.
Meanwhile, net income for the quarter jumped 16.2% to $624 million, or 65 cents a share. Walgreens net income for the same period last year was $537 million, or 62 cents a share. On Tuesday, Walgreens stock dropped nearly 6% and closed at $45.22.
“Our front-end sales are still not up to our expectations, and while the economy remains challenging, increasing customer traffic and front-end sales are our near-term priorities with a focus on pricing and promotion and the leveraging of our Balance Rewards program, which now has 75 million members,” said Greg Wasson, Walgreen’s CEO.
Walgreens’ third quarter sales rose 3.2% to $18.3 billion, which included an 8.7% increase in prescription volume. However, the company reported that customer traffic in stores decreased by 3.9%.
